169 related articles for article (PubMed ID: 7704089)
1. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
2. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
3. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
[TBL] [Abstract][Full Text] [Related]
4. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
6. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
7. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Jansson S; Morgan E
World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486
[TBL] [Abstract][Full Text] [Related]
8. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Gurney H; Grill V; Martin TJ
Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
12. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Body JJ; Dumon JC; Thirion M; Cleeren A
J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
[TBL] [Abstract][Full Text] [Related]
13. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
14. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
15. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Blind E; Raue F; Meinel T; Wüster C; Ziegler R
Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
[TBL] [Abstract][Full Text] [Related]
17. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
[TBL] [Abstract][Full Text] [Related]
18. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
Bone; 1986; 7(4):247-53. PubMed ID: 3768203
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
[TBL] [Abstract][Full Text] [Related]
20. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
